Eli Lilly

Latest Headlines

Latest Headlines

Novartis zeroes in on costs as blockbusters-to-be Cosentyx, Entresto rev up

Novartis has had a complicated year: Three months ago, the Swiss drugmaker closed its multipart asset swap with GlaxoSmithKline, sending most of its troubled vaccines business to GSK and taking on the U.K. drugmaker's oncology business.

Lilly calls in some academic muscle to get its cancer pipeline moving

Eli Lilly inked a pair of deals with Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute to hit the gas on oncology R&D, aiming to shorten the development process for a slew of new medicines.

Japan's PAFSC backs Lilly's dulaglutide, among others, in latest round

Eli Lilly Japan's once-weekly glucagon-like peptide-1 receptor agonist dulaglutide was recommended for approval by Japan's Pharmaceutical Affairs and Food Sanitation Council's (PAFSC's) First Committee on Drugs, an advisory panel to the health minister, following a June 5 meeting, an official said.

Is Lilly on the verge of an Alzheimer's turnaround?

Some early-stage success for Biogen has inaugurated something of a second honeymoon for a class of investigational Alzheimer's disease treatments, and some investors believe Eli Lilly, maker of a similar therapy, could be poised to reverse its bleak fortunes in the field.

Lilly quashes rumors of Elanco spinoff as stock soars

Eli Lilly's stock was on a tear June 9, advancing more than any other stock in the Standard & Poor's 500 Index, after investors surmised the company might be planning to spin off its animal health unit, Elanco. The rumor--which Lilly quickly tried to quiet--originally started spreading after Elanco's president, Jeffrey Simmons, spoke at a Goldman Sachs investment conference.

ADA highlights: Novo, Lilly meds top Lantus; Sanofi, AZ tout new combo regimens

The data pump is going full tilt at the American Diabetes Association meeting, with top drugmakers rolling out studies on their top drugs, new and old. From new safety analyses to head-to-head match-ups, here's a roundup of the need-to-know.

Lilly's latest lung cancer contender lines up for FDA scrutiny

Eli Lilly, angling for FDA approval for its newest lung cancer treatment, has a July 9 date with a panel of independent agency advisers, a crucial hurdle in the regulatory process.

Eli Lilly, Zoetis among stakeholders signing on to White House antibiotics plan

More than 150 food companies and animal- and human-health stakeholders publicized their efforts to combat antibiotic resistance Tuesday at a White House Forum on Antibiotic Stewardship. During the event, which was part of a multifaceted plan to reduce the use of antibiotics in food animals, President Obama signed a memorandum directing federal agencies to establish guidelines on responsible antibiotics use for meat and poultry producers.

High-profile Huntington's disease film scores on social media, but where was pharma?

HBO premiered an award-winning short documentary about Huntington's disease, a rare, hereditary neurological malady, on Monday night. The film follows actress and filmmaker Marianne Palka as she finds out the results of her genetic test. If someone has a parent with the disease as she did, they have a 50/50 chance of getting the disease. The missing voice? Pharma.

FDA approves Lilly's reformulated insulin to foster patient convenience

The FDA approved an enhanced version of Eli Lilly's Humalog U-200 KwikPen, meaning patients now have access to a concentrated mealtime insulin analog. Due to the iteration's increased concentration, the KwikPen holds twice as many units of insulin, although the three-millimeter cartridge remains unchanged.